Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $64.12 USD
Change Today -0.72 / -1.11%
Volume 2.6M
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$64.75
Previous Close
$64.84
Day High
$65.59
Day Low
$63.86
52 Week High
07/28/15 - $72.31
52 Week Low
10/15/14 - $47.36
Market Cap
54.5B
Average Volume 10 Days
5.2M
EPS TTM
--
Shares Outstanding
850.0M
EX-Date
08/18/15
P/E TM
--
Dividend
$1.36
Dividend Yield
2.09%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $3.3M
Compensation as of Fiscal Year 2014.

teva pharmaceutical-sp adr (TEVA) Key Developments

Teva Pharmaceutical Industries Announces U.S. Availability of ZECUITY

Teva Pharmaceutical Industries Ltd. announced that ZECUITY, the first and only patch system designed to provide relief from migraine, is now available by prescription through specialty pharmacies. ZECUITY is a single-use, disposable patch system that delivers sumatriptan through the skin. The device is designed to be worn for a four-hour period either on the upper arm or thigh. In a clinical study, at two hours following application, significantly more patients using ZECUITY versus a non-medicated patch system reported, as the study's primary endpoint, no headache pain (18% versus 9%). The secondary endpoints of the study showed that, at two hours following application, significantly more patients reported no nausea (84% versus 63%), no sensitivity to sound (55% versus 39%), no sensitivity to light (51% versus 36%), or headache pain relief (53% versus 29%). The most common side effects reported for ZECUITY included pain, tingling, itching, warmth, discomfort or a change in the skin color at the application site of ZECUITY. In conjunction with the availability of ZECUITY, Teva is launching Migraine Support Solutions to provide migraine education and assistance with ZECUITY including a special offer that could save patients money on their prescriptions.

Teva Pharmaceutical Industries Limited Pays RUB 300,000 Fine for Failure to Execute FAS Determination

Teva Pharmaceutical Industries Limited notified the Federal Antimonopoly Service (FAS Russia) about paying a RUB 300,000 administrative fine for failure to execute a determination issued by the antimonopoly body. In December 2013 the antimonopoly body found that TEVA violated Cause 5 Part 1 Article 10 of the Federal Law "On Protection of Competition" as a result of refusing to conclude a contract with "BIOTEK" CJSC for supplying "Copaxone" medicinal drug without any economic and technological justification and issued a determination to support competition. The Appeal Court and the Cassation Court confirmed legitimacy of the determination. In January 2014 "BIOTEK" CJSC asked TEVA twice to conclude a contact for supplying "Copaxone" but the company refused to enter into the contract. Therefore, TEVA failed to execute FAS determination and was held administratively liable and fined RUB 300,000. TEVA disagreed with the punishment and filed a lawsuit but Moscow Arbitration Court and the 9th Arbitration Appeal Court pronounced legitimacy of FAS determination.

Teva Pharmaceutical Industries Ltd. Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease

Teva Pharmaceutical Industries Ltd. announced that the New Drug Application (NDA) for SD-809 has been accepted by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington disease (HD), a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain. The NDA filing is based on positive results from two Phase-III studies, FIRST-HD and ARC-HD. In the placebo-controlled, randomized FIRST-HD study, SD-809 reduced chorea in patients with HD. Positive data from the Phase-III, open-label ARC-HD study demonstrated that patients were able to safely convert from tetrabenazine, currently the only approved HD treatment, to SD-809 overnight with continued control of chorea. SD-809 was granted Orphan Drug Designation for the treatment of HD by the FDA in November 2014 and became part of Teva’s CNS portfolio with the acquisition of Auspex Pharmaceuticals in May 2015. The FDA designates orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. SD-809 (deutetrabenazine) is an investigational, oral, small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of a specific neurotransmitter, dopamine, in the brain. SD-809 is being developed for the treatment of chorea associated with Huntington disease, a neurodegenerative movement disorder that impacts cognition, behavior, and movements. The FIRST-HD study showed a favorable safety and tolerability profile, including low rates of depression, somnolence, akathisia/restlessness and anxiety. The safety and tolerability experience observed in the ARC-HD study was consistent with the experience observed in the FIRST-HD study. The most commonly reported adverse events in ARC-HD patients were somnolence, fall, and nasopharyngitis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $64.12 USD -0.72

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.14 USD -0.10
AbbVie Inc $61.58 USD +0.60
AstraZeneca PLC 4,246 GBp -2.00
Eli Lilly & Co $81.60 USD -0.21
Medtronic PLC $69.98 USD -1.57
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 21.9x
Price/Sales 2.7x
Price/Book 2.4x
Price/Cash Flow 24.4x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.